Drugs / SC-005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03316794 | Jan → Oct 2018 | breast cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03316794 ↗ |
| Known as | Antibody-drug conjugate sc-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594494 ↗ |
| Route | Intravenous | “intravenous” NCT03316794 ↗ |